ASCELIA – AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

ADVANCING
ORPHAN ONCOLOGY

TO IMPROVE THE LIFE OF PEOPLE
LIVING WITH CANCER
BY OFFERING BETTER TREATMENT OPTIONS

Our Vision

Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.

Learn more about Ascelia Pharma:

COMPANY INTRODUCTION

TOP STORIES

Ascelia Pharma Announces FDA Acceptance of Orviglance New Drug Application for Review

2025-11-15 10:15:00

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the U.S. Food and Drug Administration (FDA) [… …

TOP STORIES

Ascelia Pharma Files New Patent Application for Orviglance

2025-11-10 09:15:00

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the filing of a new patent application for […]

TOP STORIES

Ascelia Pharma Has Completed a Directed Share Issue of Approximately SEK 30 Million

2025-09-23

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, [ …

Upcoming Events

Redeye Fight Cancer 2026

Magnus Corfitzen will participate at the Redeye Fight Cancer 2026 on January 21. To join the live presentation: Click here

Presentation of full-year report 2025 with H C Andersen

Julie Waras Brogren will present the full-year financial results for 2025 at a virtual live event To register for the presentation and submit questions in advance: Ascelia Pharma – Full […]

View all events

Latest News

Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB

Ascelia Pharma AB (publ) (ticker: ACE) today announces that the Nomination Committee for the Annual General Meeting (AGM) on 4 May 2026 has been appointed In accordance with the instructions […]

Change in Number of Shares and Votes in Ascelia Pharma AB

During the month of November, the number of shares and votes in Ascelia Pharma AB have changed due to conversion of a total of 53,335 series C shares into a […]

Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program

The Board of Directors of Ascelia Pharma AB (“Ascelia Pharma”) has on 19 November 2025 resolved to convert 53,335 series C shares into ordinary shares for delivery of shares to […]

Presentations & Articles

Redeye Life Science Day with Andreas Norlin, CSO

Andreas Norlin, Chief Scientific Officer at Ascelia Pharma presented at Redeye Life Science Day

HC Andersen – Julie Waras Brogren

Julie Waras Brogren, Deputy CEO presents first half year 2025 highlights at HC Andersen

Redeye Interview – Magnus Corfitzen presents an update on Orviglance NDA and Financing

Magnus Corfitzen, CEO of Ascelia Pharma AB, discusses the NDA submission to the FDA for Orviglance and the recent SEK 30 million share issue Redeye Interview – 25 September 2025

INVESTOR

Shortcut to our latest Financial Reports